Dynamic PET Imaging Tracks Tafamidis Effects in Cardiac Amyloidosis
Publication Title: Parametric Cardiac Imaging with 18F-Flutemetamol PET to Evaluate the Impact of Tafamidis in Patients with Transthyretin Cardiac Amyloidosis.
Summary
- Question
- This study aimed to evaluate whether dynamic imaging with a tracer called 18F-flutemetamol using positron emission tomography (PET) could measure the buildup of amyloid proteins in the heart and detect changes after six months of treatment with tafamidis. Amyloid proteins are abnormal deposits that can damage the heart in transthyretin cardiac amyloidosis (ATTR-CA), a rare but serious condition.
- Why it Matters
- ATTR-CA is a progressive disease that can lead to heart failure due to the stiffening of the heart caused by amyloid protein deposits. While tafamidis has been shown to slow disease progression, it is expensive, and there is a need for precise tools to measure its impact on the heart. This study’s findings could improve how doctors track the effectiveness of treatments and personalize care for patients with ATTR-CA.
- Methods
- The study involved 12 patients newly diagnosed with ATTR-CA who had not received previous treatment. Researchers used dynamic PET imaging with 18F-flutemetamol to scan the heart at the beginning of the study and again after six months of tafamidis treatment. Advanced imaging methods were applied to measure the distribution of the tracer in the heart, which correlates with amyloid burden.
- Key Findings
- The study showed that the volume of distribution (VT), a measure of amyloid buildup, significantly decreased after six months of tafamidis treatment, dropping from an average of 2.11 to 1.96. This suggests that tafamidis may stabilize or reduce amyloid deposits in the heart. Additionally, the imaging method was able to detect these changes with greater precision compared to traditional static imaging techniques.
- Implications
- The results indicate that dynamic 18F-flutemetamol PET imaging is a promising tool for accurately measuring amyloid burden in the heart and monitoring the effects of treatment. This approach could help healthcare providers assess the effectiveness of tafamidis and potentially other therapies, enabling better management of ATTR-CA. It may also reduce the need for invasive procedures like biopsies.
- Next Steps
- The authors suggest that future research should include larger patient groups and explore other imaging techniques or biomarkers to validate and expand upon these findings. Additional studies could also investigate how changes detected by imaging relate to long-term clinical outcomes in ATTR-CA patients.
- Funding Information
- This research was supported by a research contract from Pfizer and GE HealthCare, as well as funding for clinical trial NCT05374564. Yale University also provided funding and support for this research.
Full Citation
Liu Q, Shi T, Sharma A, De Freitas C, Fazzone-Chettiar R, Van Laere K, Baldick A, Kattan C, Guo X, Guo L, Xie H, Chen X, Zhou B, Liu Y, Carson R, Liu C, Miller E. Parametric Cardiac Imaging with 18F-Flutemetamol PET to Evaluate the Impact of Tafamidis in Patients with Transthyretin Cardiac Amyloidosis. Journal Of Nuclear Medicine 2026, 67: 780-787. PMID: 41748295, DOI: 10.2967/jnumed.125.270003.
This AI-assisted summary has been reviewed and approved by at least one of the study's authors to ensure it accurately reflects the research.
Authors
Qiong Liu
First AuthorEdward J Miller, MD, PhD
Last AuthorProfessor of Medicine (Cardiovascular Medicine)